诺和诺德Novo Nordisk (NVO) 2011年年度报告「NYSE」.pdf

1、Fi nanci al,soci al and envi ronmental performanceKey figures201 1 2011 2010 ChangeFinancial performanceSales total DKK million 66,346 60,776 9.2%Diabetes care DKK million 50,425 45,710 10.3%of which modern insulins DKK million 28,765 26,601 8.1%of which Victoza DKK million 5,991 2,317 158.6%Biophar

2、maceuticals DKK million 15,921 15,066 5.7%Gross profit DKK million 53,757 49,096 9.5%Gross margin%of sales 81.0 80.8 Sales and distribution costs%of sales 28.6 29.9 Research and development costs%of sales 14.5 15.8 Administrative expenses%of sales 4.9 5.0 Operating profit DKK million 22,374 18,891 1

3、8.4%Net profit DKK million 17,097 14,403 18.7%Effective tax rate%22.0 21.2 Capital expenditure,net DKK million 3,003 3,308(9.2%)Free cash flow DKK million 18,112 17,013 6.5%Long-termLong-term financial targets financial targets1Operating profit margin%33.7 31.1 35%Growth in operating profit%18.4 26.

4、5 15%Operating profit after tax to net operating assets1%77.9 63.6 90%Cash to earnings(three-year average)%112.8 115.6 90%Social performanceHealthcare professionals trained or educated in diabetes 1,000 835 373 123.9%Donations DKK million 81 84(3.6%)Employees(total)Number 32,632 30,483 7.0%Average o

5、f full-time employees Number 31,499 29,423 7.1%Employee turnover%9.8 9.1 Relevant employees trained in business ethics%99 98 Long-term social targets Long-termLeast developed countries where Novo Nordisk social targetssells insulin according to the differential pricing policy%75 67 100%Engaging cult

6、ure Scale 15 4.3 4.3 4.0Diverse senior management teams%62 54 100%by 2014Environmental performanceEnergy consumption 1,000 GJ 2,187 2,234(2.1%)Water consumption 1,000 m3 2,136 2,047 4.3%CO2 emissions from energy consumption 1,000 tons 93 95(2.1%)Long-termLong-term environmental targets environmental